Germany's Rentschler looks to build UK footprint with five-year investment in cell and gene therapies
Looking to add another capability to its arsenal, German CDMO Rentschler Biopharma will bump up its investment in cell and gene therapies over the next five years through a new site at the Cell and Gene Therapy Catapult in the UK.
Located in Stevenage, England, the site will allow Rentschler to establish the manufacturing of viral vectors for clinical supply. The company expects to be ready for cGMP manufacturing by the first half of 2022 and will also establish manufacturing capability in advanced therapy medicinal products, including adeno-associated virus vectors for clinical trial supply.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 148,200+ biopharma pros reading Endpoints daily — and it's free.